Pfizer BNT162b2 – 5.3.6

Pfizer BNT162b2 – 5.3.6

Vous visualisez une version nommée "Pfizer BNT162b2 - 5.3.6", enregistrée le mars 2, 2022 à 9:07 par Pr. Bösung
Titre
Pfizer BNT162b2 - 5.3.6
Contenu
BNT162b2
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports Report Prepared by : Worldwide Safety Pfizer The information contained in this document is proprietary and confidential. Any disclosure, reproduction, distribution, or other dissemination of this information outside of Pfizer, its Affiliates, its Licensees, or Regulatory Agencies is strictly prohibited. Except as may be otherwise agreed to in writing, by accepting or reviewing these materials, you agree to hold such information in confidence and not to disclose it to others (except where required by applicable law), nor to use it for unauthorized purposes.
Extrait
5.3.6 CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT REPORTS OF PF-07302048 (BNT162B2) RECEIVED THROUGH 28-FEB-2021


Anciennes Nouveau document Créé le Auteur Actions
mars 2, 2022 à 8:09 Pr. Bösung
mars 2, 2022 à 8:07 Pr. Bösung
mars 2, 2022 à 8:06 Pr. Bösung

BNT162b2
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports

Report Prepared by : Worldwide Safety

Pfizer

The information contained in this document is proprietary and confidential. Any disclosure, reproduction, distribution, or other dissemination of this information outside of Pfizer, its Affiliates, its Licensees, or Regulatory Agencies is strictly prohibited. Except as may be otherwise agreed to in writing, by accepting or reviewing these materials, you agree to hold such information in confidence and not to disclose it to others (except where required by applicable law), nor to use it for unauthorized purposes.

Share This

Share this post with your friends!